Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Mikael ErikssonMartin EklundSigne Borgquist Roxanna J HellgrenSara MargolinLinda ThorenAnn H Rosendahl Kristina Lång José TapiaMagnus BäcklundAndrea DiscacciatiAlessio Crippa Marike GabrielssonMattias HammarströmYvonne WengströmKamila CzenePer Hall

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.

Keyphrases

breast cancer risk
low dose
breast cancer cells
estrogen receptor
positive breast cancer
polycystic ovary syndrome
high dose
postmenopausal women
type diabetes
pregnancy outcomes
young adults
insulin resistance